Showing results (141-150 of 179) with videos related to

Sort By:
Pageof 18
Geburtshilfe Und Frauenheilkunde|November 1, 1989
[The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma]C Marth, R Mull, G Gastl, et al.
British Journal of Cancer|June 15, 2013
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trialV Seebacher, G Hofstetter, S Polterauer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 29, 1998
Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125A G Zeimet, F A Offner, E Müller-Holzner, et al.
International Journal of Cancer|May 15, 1989
Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblastsW Vogetseder, H Feichtinger, T F Schulz, et al.
Breast Cancer Research and Treatment|December 1, 1988
Steroid hormone receptors and prognosis in breast cancerG Daxenbichler, E P Forsthuber, C Marth, et al.
Archives of Gynecology and Obstetrics|January 23, 2018
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic OncologyA M Dueckelmann, D Fink, P Harter, et al.
British Journal of Cancer|March 29, 2000
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trialG H Windbichler, H Hausmaninger, W Stummvoll, et al.
Gynecologic Oncology|September 1, 1996
Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125A G Zeimet, C Marth, F A Offner, et al.
Archives of Gynecology and Obstetrics|February 16, 2018
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO SwitzerlandA M Dueckelmann, D Fink, P Harter, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian CancerP Harter, A du Bois, S Mahner, et al.
Pageof 18